Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Corbus Pharmaceuticals Holdings, Inc is a biotechnology business based in the US. Corbus Pharmaceuticals shares (CRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Corbus Pharmaceuticals employs 141 staff and has a trailing 12-month revenue of around USD$7.2 million.
|Latest market close||USD$1.97|
|52-week range||USD$1.39 - USD$9.78|
|50-day moving average||USD$5.7167|
|200-day moving average||USD$6.2944|
|Wall St. target price||USD$8.3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.93|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-23)||30.90%|
|1 month (2020-09-01)||-77.89%|
|3 months (2020-06-30)||-76.52%|
|6 months (2020-03-30)||-64.25%|
|1 year (2019-09-30)||-59.55%|
|2 years (2018-09-28)||-73.91%|
|3 years (2017-09-29)||-72.45%|
|5 years (2015-09-30)||25.48%|
|Revenue TTM||USD$7.2 million|
|Gross profit TTM||USD$-53,461,222|
|Return on assets TTM||-82.52%|
|Return on equity TTM||-240.39%|
|Market capitalisation||USD$125.8 million|
TTM: trailing 12 months
There are currently 15.6 million Corbus Pharmaceuticals shares held short by investors – that's known as Corbus Pharmaceuticals's "short interest". This figure is 2.4% down from 16.0 million last month.
There are a few different ways that this level of interest in shorting Corbus Pharmaceuticals shares can be evaluated.
Corbus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corbus Pharmaceuticals shares currently shorted divided by the average quantity of Corbus Pharmaceuticals shares traded daily (recently around 1.9 million). Corbus Pharmaceuticals's SIR currently stands at 8.04. In other words for every 100,000 Corbus Pharmaceuticals shares traded daily on the market, roughly 8040 shares are currently held short.
However Corbus Pharmaceuticals's short interest can also be evaluated against the total number of Corbus Pharmaceuticals shares, or, against the total number of tradable Corbus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corbus Pharmaceuticals's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Corbus Pharmaceuticals shares in existence, roughly 190 shares are currently held short) or 0.2362% of the tradable shares (for every 100,000 tradable Corbus Pharmaceuticals shares, roughly 236 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Corbus Pharmaceuticals.
Find out more about how you can short Corbus Pharmaceuticals stock.
We're not expecting Corbus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Corbus Pharmaceuticals's shares have ranged in value from as little as $1.39 up to $9.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corbus Pharmaceuticals's is 1.5373. This would suggest that Corbus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.